Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Real-time Estimate Cboe BZX
Other stock markets
 02:21:03 2024-04-24 pm EDT 		5-day change 1st Jan Change
24.57 USD -0.97% Intraday chart for 4D Molecular Therapeutics, Inc. -2.33% +21.96%
Apr. 15 Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
Apr. 15 RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT

Evolution of the average Target Price on 4D Molecular Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

236ab8d76d4959d4ee4660692ea7217.3tnuQJd0kzf8J87RcxWyFSBHxKdHKkPsK-cKLo8qFe0.6a-oc9Uf6XPOcaC0IjjqeBQooZIMYQeCYYFpafVrVLe7iNYh403XD8QW9g~c2260d66ae0fab1551a3af72ed6bdc6f

Analyst Recommendations on 4D Molecular Therapeutics, Inc.

Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating MT
BMO Capital Adjusts 4D Molecular Therapeutics' Price Target to $70 From $50, Keeps Outperform Rating MT
Powell Comments Dampen Near-Term Rate Cut Hopes, Stifling US Equity Futures Pre-Bell MT
RBC Raises PT on 4D Molecular Therapeutics to $35 From $25, Keeps Outperform Rating, Speculative Risk MT
Chardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy Rating MT
Chardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price Target MT
BofA Adjusts Price Target on 4D Molecular Therapeutics to $33 From $28, Keeps Buy Rating MT
SVB Securities Trims Price Target on 4D Molecular Therapeutics to $13 From $14, Keeps Market Perform Rating MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $14 From $15, Maintains Market Perform Rating MT
BMO Capital Starts 4D Molecular Therapeutics at Outperform With $50 Price Target MT
HC Wainwright Starts 4D Molecular Therapeutics at Buy With $36 Price Target MT
Goldman Sachs Upgrades 4D Molecular Therapeutics to Buy From Neutral, Raises Price Target to $68 From $12 MT
SVB Securities Raises 4D Molecular Therapeutics' Price Target to $15 From $11, Keeps Market Perform Rating MT
Evercore ISI Adjusts 4D Molecular Therapeutics Price Target to $45 From $32, Maintains Outperform Rating MT
SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $11 From $10, Maintains Market Perform Rating MT
SVB Securities Downgrades 4D Molecular Therapeutics to Market Perform From Outperform Rating, Adjusts Price Target to $12 From $28 MT
Jefferies Starts 4D Molecular Therapeutics at Buy With $22 Price Target MT
SVB Securities Adjusts 4D Molecular Therapeutics' Price Target to $28 from $30, Keeps Outperform Rating MT
SVB Leerink Starts 4D Molecular Therapeutics at Outperform With $30 Price Target MT
4D MOLECULAR THERAPEUTICS : BofA Securities Starts 4D Molecular Therapeutics at Buy With $47 Price Target MT
4D MOLECULAR THERAPEUTICS : Evercore ISI Starts 4D Molecular Therapeutics at Outperform With $70 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
24.81 USD
Average target price
54.22 USD
Spread / Average Target
+118.55%
High Price Target
82 USD
Spread / Highest target
+230.51%
Low Price Target
36 USD
Spread / Lowest Target
+45.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering 4D Molecular Therapeutics, Inc.

Barclays
RBC Capital Markets
BMO Capital
Jefferies & Co.
Chardan Research
BofA Securities
SVB Securities LLC
HC Wainwright
Goldman Sachs
Evercore ISI
SVB Leerink

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. Consensus 4D Molecular Therapeutics, Inc.